Quest Diagnostics Launches Testing for Oropouche Virus: A Step Forward in Public Health Preparedness

On July 15, 2025, Quest Diagnostics Inc. (NYSE: DGX), a prominent provider of diagnostic information services, announced the launch of a new laboratory test aimed at detecting the Oropouche virus. This emerging infectious disease, primarily found in parts of South and Central America as well as the Caribbean, poses a growing concern for public health, particularly as travel patterns continue to evolve in a post-pandemic world.

Yuri Fesko, MD, Senior Vice President and Chief Medical Officer at Quest Diagnostics, emphasized the role of the company in preparing the U.S. healthcare system for potential public health threats. “As one of the leading providers of laboratory testing, Quest plays an essential role in ensuring the U.S. is prepared to respond to potentially dangerous emerging diseases, such as Oropouche virus,” he stated. By introducing this diagnostic test, Quest aims to provide scalable testing support to public health laboratories, should the virus escalate into a more significant health threat.

The Oropouche virus is transmitted to humans through infected biting midges and certain species of mosquitoes. Although the immediate threat in North America remains low, the virus has been documented in various regions of South America, Central America, and the Caribbean, where a significant number of infected individuals exhibit symptoms. Cases in the U.S. have largely been limited to travelers returning from endemic areas.

The clinical presentation of Oropouche viral disease can mimic other arboviral illnesses like Dengue, Zika, and chikungunya. While most individuals recover without any complications, the virus can lead to more severe neuroinvasive conditions, including meningitis and encephalitis, emphasizing the need for accurate and timely diagnoses.

The new Oropouche virus test will become available by the end of July 2025, provided through a prescription from healthcare providers for clinical use. Quest Diagnostics’ advanced laboratory located in San Juan Capistrano, California, is responsible for developing and performing this test utilizing cutting-edge polymerase chain reaction (PCR) technology.

The initial phase of the testing will employ reverse transcription PCR to detect the virus's RNA during the early stages of infection, facilitating prompt diagnosis. Additionally, serology testing is expected to follow later in the quarter, allowing for the identification of antibodies produced by the immune system in response to the virus, which can aid in diagnosing individuals in later stages of infection.

Quest Diagnostics has been proactive in addressing emerging infectious diseases. In September 2024, the company received multiple contracts from the U.S. Centers for Disease Control and Prevention (CDC) aimed at supporting testing and maintaining laboratory readiness for such diseases, including Oropouche virus. These contracts provide essential funding to ensure that the company can sustain its testing capabilities, including maintaining adequate supplies of necessary equipment and chemical reagents, enabling a swift public health response when needed.

The introduction of the Oropouche virus test by Quest Diagnostics marks a significant advancement in public health preparedness in the face of emerging infectious diseases. As the world continues to navigate the complexities of global health threats, the ability to quickly identify and respond to such viruses is crucial. With nearly 55,000 employees dedicated to transforming diagnostic insights into actionable health outcomes, Quest Diagnostics remains at the forefront of safeguarding public health through innovative testing solutions.

As this new diagnostic capability rolls out, the healthcare community and the public alike will be better equipped to understand and manage the risks associated with the Oropouche virus, potentially mitigating its impact on health systems and communities across the nation.